Trafficking of Dendritic Cells in the Tumor Environment



To initiate immune responses, dendritic cells follow a migratory route from their recruitment as sentinels into tissues, including solid tumors, then to secondary lymphoid organs where they contour the immune response. Migratory capacities and chemokine responsiveness are therefore key elements in dendritic cell immunobiology. Tumor-derived factors alter dendritic cell maturation and function and thus markedly affect dendritic cell trafficking and distribution. Tumor-mediated down-regulation or redirection of dendritic cell migration and homing may markedly alter a normal pattern of dendritic cell localization and thus induction of antitumor immunity in tumor-bearing hosts, and might also strongly inhibit the efficacy of dendritic cell vaccines. Improved understanding of the regulation of DC trafficking might offer new opportunities for therapeutic interventions to control immune responses. Given the current interest in applying dendritic cell-based immunotherapy to cancer treatment, an understanding of the molecular defects responsible for dysfunction of dendritic cell trafficking and biodistribution in cancer is essential for designing and testing the next generation of dendritic cell vaccines.


Dendritic Cell Drain Lymph Node Immature Dendritic Cell Dendritic Cell Vaccine Dendritic Cell Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Adema, G. J., de Vries, I. J., Punt, C. J. and Figdor, C. G. 2005. Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol 17:170–174.PubMedCrossRefGoogle Scholar
  2. Ahmed, S. U., Okamoto, M., Oshikawa, T., Tano, T., Sasai, A., Kan, S., Hiroshima, T., Ohue, H., Moriya, Y., Ryoma, Y., Saito, M. and Sato, M. 2004. Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like receptor 4. J Immunother 27:432–441.PubMedCrossRefGoogle Scholar
  3. Allan, C. P., Turtle, C. J., Mainwaring, P. N., Pyke, C. and Hart, D. N. 2004. The immune response to breast cancer, and the case for DC immunotherapy. Cytotherapy 6:154–163.PubMedCrossRefGoogle Scholar
  4. Allan, R. S., Waithman, J., Bedoui, S., Jones, C. M., Villadangos, J. A., Zhan, Y., Lew, A. M., Shortman, K., Heath, W. R. and Carbone, F. R. 2006. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 25:153–162.PubMedCrossRefGoogle Scholar
  5. Allavena, P., Sica, A., Vecchi, A., Locati, M., Sozzani, S. and Mantovani, A. 2000. The chemokine receptor switch paradigm and dendritic cell migration: its significance in tumor tissues. Immunol Rev 177:141–149.PubMedCrossRefGoogle Scholar
  6. Bachmann, M. F., Kopf, M. and Marsland, B. J. 2006. Chemokines: more than just road signs. Nat Rev Immunol 6:159–164.PubMedCrossRefGoogle Scholar
  7. Baratelli, F. E., Heuze-Vourc'h, N., Krysan, K., Dohadwala, M., Riedl, K., Sharma, S. and Dubinett, S. M. 2004. Prostaglandin E2-dependent enhancement of tissue inhibitors of metalloproteinases-1 production limits dendritic cell migration through extracellular matrix. J Immunol 173:5458–5466.PubMedGoogle Scholar
  8. Becker, Y. 1992. Anticancer role of dendritic cells (DC) in human and experimental cancers – a review. Anticancer Res 12:511–520.PubMedGoogle Scholar
  9. Bell, D., Chomarat, P., Broyles, D., Netto, G., Harb, G. M., Lebecque, S., Valladeau, J., Davoust, J., Palucka, K. A. and Banchereau, J. 1999. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 190:1417–1426.PubMedCrossRefGoogle Scholar
  10. Bennaceur, K., Chapman, J., Brikci-Nigassa, L., Sanhadji, K., Touraine, J. L. and Portoukalian, J. 2008. Dendritic cells dysfunction in tumour environment. Cancer Lett 272(2):186–196.Google Scholar
  11. Bennaceur, K., Popa, I., Portoukalian, J., Berthier-Vergnes, O. and Peguet-Navarro, J. 2006. Melanoma-derived gangliosides impair migratory and antigen-presenting function of human epidermal Langerhans cells and induce their apoptosis. Int Immunol 18:879–886.PubMedCrossRefGoogle Scholar
  12. Berthier-Vergnes, O., Bermond, F., Flacher, V., Massacrier, C., Schmitt, D. and Peguet-Navarro, J. 2005. TNF-alpha enhances phenotypic and functional maturation of human epidermal Langerhans cells and induces IL-12 p40 and IP-10/CXCL-10 production. FEBS Lett 579:3660–3668.PubMedCrossRefGoogle Scholar
  13. Bertho, N., Adamski, H., Toujas, L., Debove, M., Davoust, J. and Quillien, V. 2005. Efficient migration of dendritic cells toward lymph node chemokines and induction of T(H)1 responses require maturation stimulus and apoptotic cell interaction. Blood 106:1734–1741.PubMedCrossRefGoogle Scholar
  14. Blocklet, D., Toungouz, M., Kiss, R., Lambermont, M., Velu, T., Duriau, D., Goldman, M. and Goldman, S. 2003. 111In-oxine and 99mTc-HMPAO labelling of antigen-loaded dendritic cells: in vivo imaging and influence on motility and actin content. Eur J Nucl Med Mol Imaging 30:440–447.PubMedCrossRefGoogle Scholar
  15. Burnet, M. 1957. Cancer; a biological approach. I. The processes of control. Br Med J 1:779–786.Google Scholar
  16. Candido, K. A., Shimizu, K., McLaughlin, J. C., Kunkel, R., Fuller, J. A., Redman, B. G., Thomas, E. K., Nickoloff, B. J. and Mule, J. J. 2001. Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents. Cancer Res 61:228–236.PubMedGoogle Scholar
  17. Carbone, F. R., Belz, G. T. and Heath, W. R. 2004. Transfer of antigen between migrating and lymph node-resident DCs in peripheral T-cell tolerance and immunity. Trends Immunol 25:655–658.PubMedCrossRefGoogle Scholar
  18. Caux, C., Ait-Yahia, S., Chemin, K., de Bouteiller, O., Dieu-Nosjean, M. C., Homey, B., Massacrier, C., Vanbervliet, B., Zlotnik, A. and Vicari, A. 2000. Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin Immunopathol 22:345–369.PubMedCrossRefGoogle Scholar
  19. Cavanagh, L. L. and Weninger, W. 2008. Dendritic cell behaviour in vivo: lessons learned from intravital two-photon microscopy. Immunol Cell Biol 86:428–438.PubMedCrossRefGoogle Scholar
  20. Chi, K. H., Liu, S. J., Li, C. P., Kuo, H. P., Wang, Y. S., Chao, Y. and Hsieh, S. L. 2005. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother 28:129–135.PubMedCrossRefGoogle Scholar
  21. Choi, Y. K., Fallert, B. A., Murphey-Corb, M. A. and Reinhart, T. A. 2003. Simian immunodeficiency virus dramatically alters expression of homeostatic chemokines and dendritic cell markers during infection in vivo. Blood 101:1684–1691.PubMedCrossRefGoogle Scholar
  22. Crittenden, M. R., Thanarajasingam, U., Vile, R. G. and Gough, M. J. 2005. Intratumoral immunotherapy: using the tumour against itself. Immunology 114:11–22.PubMedCrossRefGoogle Scholar
  23. Curti, A., Tosi, P., Comoli, P., Terragna, C., Ferri, E., Cellini, C., Massaia, M., D'Addio, A., Giudice, V., Di Bello, C., Cavo, M., Conte, R., Gugliotta, G., Baccarani, M. and Lemoli, R. M. 2007. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. Br J Haematol 139:415–424.PubMedCrossRefGoogle Scholar
  24. Darmanin, S., Chen, J., Zhao, S., Cui, H., Shirkoohi, R., Kubo, N., Kuge, Y., Tamaki, N., Nakagawa, K., Hamada, J., Moriuchi, T. and Kobayashi, M. 2007. All-trans retinoic acid enhances murine dendritic cell migration to draining lymph nodes via the balance of matrix metalloproteinases and their inhibitors. J Immunol 179:4616–4625.PubMedGoogle Scholar
  25. de Vries, I. J., Lesterhuis, W. J., Barentsz, J. O., Verdijk, P., van Krieken, J. H., Boerman, O. C., Oyen, W. J., Bonenkamp, J. J., Boezeman, J. B., Adema, G. J., Bulte, J. W., Scheenen, T. W., Punt, C. J., Heerschap, A. and Figdor, C. G. 2005. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 23:1407–1413.PubMedCrossRefGoogle Scholar
  26. Del Prete, A., Shao, W. H., Mitola, S., Santoro, G., Sozzani, S. and Haribabu, B. 2007. Regulation of dendritic cell migration and adaptive immune response by leukotriene B4 receptors: a role for LTB4 in up-regulation of CCR7 expression and function. Blood 109:626–631.PubMedCrossRefGoogle Scholar
  27. Dieu, M. C., Vanbervliet, B., Vicari, A., Bridon, J. M., Oldham, E., Ait-Yahia, S., Briere, F., Zlotnik, A., Lebecque, S. and Caux, C. 1998. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 188:373–386.PubMedCrossRefGoogle Scholar
  28. Eggert, A. A., Schreurs, M. W., Boerman, O. C., Oyen, W. J., de Boer, A. J., Punt, C. J., Figdor, C. G. and Adema, G. J. 1999. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 59:3340–3345.PubMedGoogle Scholar
  29. Eggert, A. A., van der Voort, R., Torensma, R., Moulin, V., Boerman, O. C., Oyen, W. J., Punt, C. J., Diepstra, H., de Boer, A. J., Figdor, C. G. and Adema, G. J. 2003. Analysis of dendritic cell trafficking using EGFP-transgenic mice. Immunol Lett 89:17–24.PubMedCrossRefGoogle Scholar
  30. Ehtesham, M., Kabos, P., Gutierrez, M. A., Samoto, K., Black, K. L. and Yu, J. S. 2003. Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats. J Immunother 26:107–116.PubMedCrossRefGoogle Scholar
  31. Eisenthal, A., Polyvkin, N., Bramante-Schreiber, L., Misonznik, F., Hassner, A. and Lifschitz-Mercer, B. 2001. Expression of dendritic cells in ovarian tumors correlates with clinical outcome in patients with ovarian cancer. Hum Pathol 32:803–807.PubMedCrossRefGoogle Scholar
  32. Esche, C., Lokshin, A., Shurin, G. V., Gastman, B. R., Rabinowich, H., Watkins, S. C., Lotze, M. T. and Shurin, M. R. 1999. Tumor's other immune targets: dendritic cells. J Leukoc Biol 66:336–344.PubMedGoogle Scholar
  33. Esche, C., Shurin, G. V., Kirkwood, J. M., Wang, G. Q., Rabinowich, H., Pirtskhalaishvili, G. and Shurin, M. R. 2001. Tumor necrosis factor-alpha-promoted expression of Bcl-2 and inhibition of mitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanoma-induced apoptosis. Clin Cancer Res 7:974s–979.PubMedGoogle Scholar
  34. Feijoo, E., Alfaro, C., Mazzolini, G., Serra, P., Penuelas, I., Arina, A., Huarte, E., Tirapu, I., Palencia, B., Murillo, O., Ruiz, J., Sangro, B., Richter, J. A., Prieto, J. and Melero, I. 2005. Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int J Cancer 116:275–281.PubMedCrossRefGoogle Scholar
  35. Fioretti, F., Fradelizi, D., Stoppacciaro, A., Ramponi, S., Ruco, L., Minty, A., Sozzani, S., Garlanda, C., Vecchi, A. and Mantovani, A. 1998. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. J Immunol 161:342–346.PubMedGoogle Scholar
  36. Frederick, M. J., Henderson, Y., Xu, X., Deavers, M. T., Sahin, A. A., Wu, H., Lewis, D. E., El-Naggar, A. K. and Clayman, G. L. 2000. In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol 156:1937–1950.PubMedCrossRefGoogle Scholar
  37. Frenzel, H., Pries, R., Brocks, C. P., Jabs, W. J., Wittkopf, N. and Wollenberg, B. 2007. Decreased migration of myeloid dendritic cells through increased levels of C-reactive protein. Anticancer Res 27:4111–4115.PubMedGoogle Scholar
  38. Fushimi, T., Kojima, A., Moore, M. A. and Crystal, R. G. 2000. Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J Clin Invest 105:1383–1393.PubMedCrossRefGoogle Scholar
  39. Gabrilovich, D. I., Corak, J., Ciernik, I. F., Kavanaugh, D. and Carbone, D. P. 1997. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3:483–490.PubMedGoogle Scholar
  40. Giovarelli, M., Cappello, P., Forni, G., Salcedo, T., Moore, P. A., LeFleur, D. W., Nardelli, B., Carlo, E. D., Lollini, P. L., Ruben, S., Ullrich, S., Garotta, G. and Musiani, P. 2000. Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes. J Immunol 164:3200–3206.PubMedGoogle Scholar
  41. Grover, A., Kim, G. J., Lizee, G., Tschoi, M., Wang, G., Wunderlich, J. R., Rosenberg, S. A., Hwang, S. T. and Hwu, P. 2006. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin Cancer Res 12:5801–5808.PubMedCrossRefGoogle Scholar
  42. Gunn, M. D., Kyuwa, S., Tam, C., Kakiuchi, T., Matsuzawa, A., Williams, L. T. and Nakano, H. 1999. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med 189:451–460.PubMedCrossRefGoogle Scholar
  43. Halliday, G. M., Lucas, A. D. and Barnetson, R. S. 1992. Control of Langerhans' cell density by a skin tumour-derived cytokine. Immunology 77:13–18.PubMedGoogle Scholar
  44. Hirao, M., Onai, N., Hiroishi, K., Watkins, S. C., Matsushima, K., Robbins, P. D., Lotze, M. T. and Tahara, H. 2000. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res 60:2209–2217.PubMedGoogle Scholar
  45. Horiguchi, S., Matsuoka, T., Okamoto, Y., Sakurai, D., Kobayashi, K., Chazono, H., Hanazawa, T. and Tanaka, Y. 2007. Migration of tumor antigen-pulsed dendritic cells after mucosal administration in the human upper respiratory tract. J Clin Immunol 27:598–604.PubMedCrossRefGoogle Scholar
  46. Hromas, R., Broxmeyer, H. E., Kim, C., Nakshatri, H., Christopherson, K., II, Azam, M. and Hou, Y. H. 1999. Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells. Biochem Biophys Res Commun 255:703–706.PubMedCrossRefGoogle Scholar
  47. Huang, H. L., Wu, B. Y., You, W. D., Shen, M. S. and Wang, W. J. 2003. Influence of dendritic cell infiltration on prognosis and biologic characteristics of progressing gastric cancer. Zhonghua Zhong Liu Za Zhi 25:468–471.PubMedGoogle Scholar
  48. Huck, S. P., Tang, S. C., Andrew, K. A., Yang, J., Harper, J. L. and Ronchese, F. 2008. Activation and route of administration both determine the ability of bone marrow-derived dendritic cells to accumulate in secondary lymphoid organs and prime CD8+ T cells against tumors. Cancer Immunol Immunother 57:63–71.PubMedCrossRefGoogle Scholar
  49. Katsenelson, N. S., Shurin, G. V., Bykovskaia, S. N., Shogan, J. and Shurin, M. R. 2001. Human small cell lung carcinoma and carcinoid tumor regulate dendritic cell maturation and function. Mod Pathol 14:40–45.PubMedCrossRefGoogle Scholar
  50. Keast, D. 1970. Immunosurveillance and cancer. Lancet 2:710–712.PubMedCrossRefGoogle Scholar
  51. Kikuchi, K., Kusama, K., Taguchi, K., Ishikawa, F., Okamoto, M., Shimada, J., Sakashita, H. and Yamamo, Y. 2002. Dendritic cells in human squamous cell carcinoma of the oral cavity. Anticancer Res 22:545–557.PubMedGoogle Scholar
  52. Kirk, C. J., Hartigan-O'Connor, D., Nickoloff, B. J., Chamberlain, J. S., Giedlin, M., Aukerman, L. and Mule, J. J. 2001. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 61:2062–2070.PubMedGoogle Scholar
  53. Ladanyi, A., Kiss, J., Somlai, B., Gilde, K., Fejos, Z., Mohos, A., Gaudi, I. and Timar, J. 2007. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 56:1459–1469.PubMedCrossRefGoogle Scholar
  54. Lanzavecchia, A. and Sallusto, F. 2001. The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. Curr Opin Immunol 13:291–298.PubMedCrossRefGoogle Scholar
  55. Mackensen, A., Krause, T., Blum, U., Uhrmeister, P., Mertelsmann, R. and Lindemann, A. 1999. Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. Cancer Immunol Immunother 48:118–122.PubMedCrossRefGoogle Scholar
  56. Mantovani, A., Allavena, P., Vecchi, A. and Sozzani, S. 1998. Chemokines and chemokine receptors during activation and deactivation of monocytes and dendritic cells and in amplification of Th1 versus Th2 responses. Int J Clin Lab Res 28:77–82.PubMedCrossRefGoogle Scholar
  57. MartIn-Fontecha, A., Sebastiani, S., Hopken, U. E., Uguccioni, M., Lipp, M., Lanzavecchia, A. and Sallusto, F. 2003. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 198:615–621.PubMedCrossRefGoogle Scholar
  58. Mazzolini, G., Alfaro, C., Sangro, B., Feijoo, E., Ruiz, J., Benito, A., Tirapu, I., Arina, A., Sola, J., Herraiz, M., Lucena, F., Olague, C., Subtil, J., Quiroga, J., Herrero, I., Sadaba, B., Bendandi, M., Qian, C., Prieto, J. and Melero, I. 2005. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol 23:999–1010.PubMedCrossRefGoogle Scholar
  59. McColl, S. R. 2002. Chemokines and dendritic cells: a crucial alliance. Immunol Cell Biol 80:489–496.PubMedCrossRefGoogle Scholar
  60. McWilliam, A. S., Napoli, S., Marsh, A. M., Pemper, F. L., Nelson, D. J., Pimm, C. L., Stumbles, P. A., Wells, T. N. and Holt, P. G. 1996. Dendritic cells are recruited into the airway epithelium during the inflammatory response to a broad spectrum of stimuli. J Exp Med 184:2429–2432.PubMedCrossRefGoogle Scholar
  61. Melcher, A., Todryk, S., Bateman, A., Chong, H., Lemoine, N. R. and Vile, R. G. 1999. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity. Cancer Res 59:2802–2805.PubMedGoogle Scholar
  62. Melero, I., Vile, R. G. and Colombo, M. P. 2000. Feeding dendritic cells with tumor antigens: self-service buffet or a la carte? Gene Ther 7:1167–1170.PubMedCrossRefGoogle Scholar
  63. Morse, M. A., Coleman, R. E., Akabani, G., Niehaus, N., Coleman, D. and Lyerly, H. K. 1999. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 59:56–58.PubMedGoogle Scholar
  64. Mueller, S. N., Hosiawa-Meagher, K. A., Konieczny, B. T., Sullivan, B. M., Bachmann, M. F., Locksley, R. M., Ahmed, R. and Matloubian, M. 2007. Regulation of homeostatic chemokine expression and cell trafficking during immune responses. Science 317:670–674.PubMedCrossRefGoogle Scholar
  65. Mullins, D. W., Sheasley, S. L., Ream, R. M., Bullock, T. N., Fu, Y. X. and Engelhard, V. H. 2003. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 198:1023–1034.PubMedCrossRefGoogle Scholar
  66. Nakakubo, Y., Miyamoto, M., Cho, Y., Hida, Y., Oshikiri, T., Suzuoki, M., Hiraoka, K., Itoh, T., Kondo, S. and Katoh, H. 2003. Clinical significance of immune cell infiltration within gallbladder cancer. Br J Cancer 89:1736–1742.PubMedCrossRefGoogle Scholar
  67. Okada, N., Mori, N., Koretomo, R., Okada, Y., Nakayama, T., Yoshie, O., Mizuguchi, H., Hayakawa, T., Nakagawa, S., Mayumi, T., Fujita, T. and Yamamoto, A. 2005. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction. Gene Ther 12:129–139.PubMedCrossRefGoogle Scholar
  68. Palucka, A. K., Laupeze, B., Aspord, C., Saito, H., Jego, G., Fay, J., Paczesny, S., Pascual, V. and Banchereau, J. 2005. Immunotherapy via dendritic cells. Adv Exp Med Biol 560:105–114.PubMedCrossRefGoogle Scholar
  69. Pirtskhalaishvili, G., Shurin, G. V., Esche, C., Cai, Q., Salup, R. R., Bykovskaia, S. N., Lotze, M. T. and Shurin, M. R. 2000a. Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. Br J Cancer 83:506–513.PubMedCrossRefGoogle Scholar
  70. Pirtskhalaishvili, G., Shurin, G. V., Esche, C., Trump, D. L. and Shurin, M. R. 2001. TNF-alpha protects dendritic cells from prostate cancer-induced apoptosis. Prostate Cancer Prostatic Dis 4:221–227.PubMedCrossRefGoogle Scholar
  71. Pirtskhalaishvili, G., Shurin, G. V., Gambotto, A., Esche, C., Wahl, M., Yurkovetsky, Z. R., Robbins, P. D. and Shurin, M. R. 2000b. Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice. J Immunol 165:1956–1964.PubMedGoogle Scholar
  72. Prince, H. M., Wall, D. M., Ritchie, D., Honemann, D., Harrrison, S., Quach, H., Thompson, M., Hicks, R., Lau, E., Davison, J., Loudovaris, M., Moloney, J., Loveland, B., Bartholeyns, J., Katsifis, A. and Mileshkin, L. 2008. In vivo tracking of dendritic cells in patients with multiple myeloma. J Immunother 31:166–179.PubMedCrossRefGoogle Scholar
  73. Qu, X., Yang, M. X., Kong, B. H., Qi, L., Lam, Q. L., Yan, S., Li, P., Zhang, M. and Lu, L. 2005. Hypoxia inhibits the migratory capacity of human monocyte-derived dendritic cells. Immunol Cell Biol 83:668–673.PubMedCrossRefGoogle Scholar
  74. Quillien, V., Moisan, A., Carsin, A., Lesimple, T., Lefeuvre, C., Adamski, H., Bertho, N., Devillers, A., Leberre, C. and Toujas, L. 2005. Biodistribution of radiolabelled human dendritic cells injected by various routes. Eur J Nucl Med Mol Imaging 32:731–741.PubMedCrossRefGoogle Scholar
  75. Randolph, G. J., Angeli, V. and Swartz, M. A. 2005. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol 5:617–628.PubMedCrossRefGoogle Scholar
  76. Randolph, G. J., Ochando, J. and Partida-Sanchez, S. 2008. Migration of dendritic cell subsets and their precursors. Annu Rev Immunol 26:293–316.PubMedCrossRefGoogle Scholar
  77. Reichert, T. E., Scheuer, C., Day, R., Wagner, W. and Whiteside, T. L. 2001. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 91:2136–2147.PubMedCrossRefGoogle Scholar
  78. Remmel, E., Terracciano, L., Noppen, C., Zajac, P., Heberer, M., Spagnoli, G. C. and Padovan, E. 2001. Modulation of dendritic cell phenotype and mobility by tumor cells in vitro. Hum Immunol 62:39–49.PubMedCrossRefGoogle Scholar
  79. Rescigno, M., Granucci, F. and Ricciardi-Castagnoli, P. 1999. Dendritic cells at the end of the millennium. Immunol Cell Biol 77:404–410.PubMedCrossRefGoogle Scholar
  80. Robert, C., Fuhlbrigge, R. C., Kieffer, J. D., Ayehunie, S., Hynes, R. O., Cheng, G., Grabbe, S., von Andrian, U. H. and Kupper, T. S. 1999. Interaction of dendritic cells with skin endothelium: A new perspective on immunosurveillance. J Exp Med 189:627–636.PubMedCrossRefGoogle Scholar
  81. Rossowska, J., Pajtasz-Piasecka, E., Szyda, A., Zietara, N. and Dus, D. 2007. Tissue localization of tumor antigen-loaded mouse dendritic cells applied as an anti-tumor vaccine and their influence on immune response. Folia Histochem Cytobiol 45:349–355.PubMedGoogle Scholar
  82. Sallusto, F., Schaerli, P., Loetscher, P., Schaniel, C., Lenig, D., Mackay, C. R., Qin, S. and Lanzavecchia, A. 1998. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 28:2760–2769.PubMedCrossRefGoogle Scholar
  83. Sandel, M. H., Dadabayev, A. R., Menon, A. G., Morreau, H., Melief, C. J., Offringa, R., van der Burg, S. H., Janssen-van Rhijn, C. M., Ensink, N. G., Tollenaar, R. A., van de Velde, C. J. and Kuppen, P. J. 2005. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res 11:2576–2582.PubMedCrossRefGoogle Scholar
  84. Scarpino, S., Stoppacciaro, A., Ballerini, F., Marchesi, M., Prat, M., Stella, M. C., Sozzani, S., Allavena, P., Mantovani, A. and Ruco, L. P. 2000. Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. Am J Pathol 156:831–837.PubMedCrossRefGoogle Scholar
  85. Schuler, G., Schuler-Thurner, B. and Steinman, R. M. 2003. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15:138–147.PubMedCrossRefGoogle Scholar
  86. Shurin, G. V., Ferris, R., Tourkova, I. L., Perez, L., Lokshin, A., Balkir, L., Collins, B., Chatta, G. S. and Shurin, M. R. 2005a. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J Immunol 174:5490–5498.PubMedGoogle Scholar
  87. Shurin, G. V., Shurin, M. R., Bykovskaia, S., Shogan, J., Lotze, M. T. and Barksdale, E. M., Jr. 2001. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res 61:363–369.PubMedGoogle Scholar
  88. Shurin, G. V., Tourkova, I. L., Chatta, G. S., Schmidt, G., Wei, S., Djeu, J. Y. and Shurin, M. R. 2005b. Small rho GTPases regulate antigen presentation in dendritic cells. J Immunol 174:3394–3400.PubMedGoogle Scholar
  89. Shurin, M. R. and Gabrilovich, D. I. 2001. Regulation of dendritic cell system by tumor. Cancer Res Ther Control 11:65–78.Google Scholar
  90. Shurin, M. R., Shurin, G. V., Lokshin, A., Yurkovetsky, Z. R., Gutkin, D. W., Chatta, G., Zhong, H., Han, B. and Ferris, R. L. 2006. Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev 25:333–356.PubMedCrossRefGoogle Scholar
  91. Stagg, J., Johnstone, R. W. and Smyth, M. J. 2007. From cancer immunosurveillance to cancer immunotherapy. Immunol Rev 220:82–101.PubMedCrossRefGoogle Scholar
  92. Starnes, T., Rasila, K. K., Robertson, M. J., Brahmi, Z., Dahl, R., Christopherson, K. and Hromas, R. 2006. The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy. Exp Hematol 34:1101–1105.PubMedCrossRefGoogle Scholar
  93. Takayama, T., Morelli, A. E., Onai, N., Hirao, M., Matsushima, K., Tahara, H. and Thomson, A. W. 2001. Mammalian and viral IL-10 enhance C–C chemokine receptor 5 but down-regulate C–C chemokine receptor 7 expression by myeloid dendritic cells: impact on chemotactic responses and in vivo homing ability. J Immunol 166:7136–7143.PubMedGoogle Scholar
  94. Thomas, R., Chambers, M., Boytar, R., Barker, K., Cavanagh, L. L., MacFadyen, S., Smithers, M., Jenkins, M. and Andersen, J. 1999. Immature human monocyte-derived dendritic cells migrate rapidly to draining lymph nodes after intradermal injection for melanoma immunotherapy. Melanoma Res 9:474–481.PubMedCrossRefGoogle Scholar
  95. Tong, Y., Song, W. and Crystal, R. G. 2001. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res 61:7530–7535.PubMedGoogle Scholar
  96. Tourkova, I. L., Shurin, G. V., Chatta, G. S., Perez, L., Finke, J., Whiteside, T. L., Ferrone, S. and Shurin, M. R. 2005. Restoration by IL-15 of MHC class I antigen-processing machinery in human dendritic cells inhibited by tumor-derived gangliosides. J Immunol 175:3045–3052.PubMedGoogle Scholar
  97. Tourkova, I. L., Shurin, G. V., Wei, S. and Shurin, M. R. 2007. Small rho GTPases mediate tumor-induced inhibition of endocytic activity of dendritic cells. J Immunol 178:7787–7793.PubMedGoogle Scholar
  98. Tourkova, I. L., Yurkovetsky, Z. R., Gambotto, A., Makarenkova, V. P., Perez, L., Balkir, L., Robbins, P. D., Shurin, M. R. and Shurin, G. V. 2002. Increased function and survival of IL-15-transduced human dendritic cells are mediated by up-regulation of IL-15Ralpha and Bcl-2. J Leukoc Biol 72:1037–1045.PubMedGoogle Scholar
  99. Triozzi, P. L., Khurram, R., Aldrich, W. A., Walker, M. J., Kim, J. A. and Jaynes, S. 2000. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer 89:2646–2654.PubMedCrossRefGoogle Scholar
  100. Vanderheyde, N., Aksoy, E., Amraoui, Z., Vandenabeele, P., Goldman, M. and Willems, F. 2001. Tumoricidal activity of monocyte-derived dendritic cells: evidence for a caspase-8-dependent, Fas-associated death domain-independent mechanism. J Immunol 167:3565–3569.PubMedGoogle Scholar
  101. Verdijk, P., Aarntzen, E. H., Punt, C. J., de Vries, I. J. and Figdor, C. G. 2008. Maximizing dendritic cell migration in cancer immunotherapy. Expert Opin Biol Ther 8:865–874.PubMedCrossRefGoogle Scholar
  102. Vicari, A. P., Ait-Yahia, S., Chemin, K., Mueller, A., Zlotnik, A. and Caux, C. 2000. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol 165:1992–2000.PubMedGoogle Scholar
  103. Vicari, A. P., Treilleux, I. and Lebecque, S. 2004. Regulation of the trafficking of tumour-infiltrating dendritic cells by chemokines. Semin Cancer Biol 14:161–169.PubMedCrossRefGoogle Scholar
  104. Walker, S. R., Aboka, A., Ogagan, P. D. and Barksdale, E. M., Jr. 2005. Murine neuroblastoma attenuates dendritic cell cysteine cysteine receptor 7 (CCR7) expression. J Pediatr Surg 40:983–987.PubMedCrossRefGoogle Scholar
  105. Yang, L. and Carbone, D. P. 2004. Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 92:13–27.PubMedCrossRefGoogle Scholar
  106. Yang, R., Xu, D., Zhang, A. and Gruber, A. 2001. Immature dendritic cells kill ovarian carcinoma cells by a FAS/FASL pathway, enabling them to sensitize tumor-specific CTLs. Int J Cancer 94:407–413.PubMedCrossRefGoogle Scholar
  107. Yen, J. H., Khayrullina, T. and Ganea, D. 2008. PGE2-induced metalloproteinase-9 is essential for dendritic cell migration. Blood 111:260–270.PubMedCrossRefGoogle Scholar
  108. Yoneyama, H., Matsuno, K. and Matsushimaa, K. 2005. Migration of dendritic cells. Int J Hematol 81:204–207.PubMedCrossRefGoogle Scholar
  109. Yoshie, O. 2000. Role of chemokines in trafficking of lymphocytes and dendritic cells. Int J Hematol 72:399–407.PubMedGoogle Scholar
  110. Yurkovetsky, Z. R., Shurin, G. V., Barry, D. A., Schuh, A. C., Shurin, M. R. and Robbins, P. D. 2006. Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells. J Gene Med 8:129–137.PubMedCrossRefGoogle Scholar
  111. Zhong, H., Shurin, M. R. and Han, B. 2007. Optimizing dendritic cell-based immunotherapy for cancer. Expert Rev Vaccines 6:333–345.PubMedCrossRefGoogle Scholar
  112. Zou, W., Machelon, V., Coulomb-L'Hermin, A., Borvak, J., Nome, F., Isaeva, T., Wei, S., Krzysiek, R., Durand-Gasselin, I., Gordon, A., Pustilnik, T., Curiel, D. T., Galanaud, P., Capron, F., Emilie, D. and Curiel, T. J. 2001. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 7:1339–1346.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.University of Pittsburgh Medical CenterPittsburghUSA

Personalised recommendations